Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV-infected males and non-pregnant/non-lactating females~* Treatment naive or treatment experienced individuals~* Child-Pugh-Turcotte Score 7-12 at screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks
- SOF/VEL + RBV (Type: EXPERIMENTAL): SOF/VEL + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).